Moreover, the intermediate/poor, intermediate, and poor prognosis sub-populations, patients with higher THBS1 expression also showed longer survival times (Figures 2D–F), suggesting that THBS1 might be a prognostic biomarker for AML patients. This evidence concerns the gene THBS1 and acute myeloid leukemia.